68Ga-FAPI PET/CT在乳腺癌疗效评估与随访中的作用
本研究对6例FAPI高摄取的浸润性小叶乳腺癌患者进行治疗前后随访,共行24次扫描,将68Ga-FAPI最大强度投影定性图像和定量肿瘤体积与CT结果及血液肿瘤生物标志物进行相关性分析。结果显示68Ga-FAPI肿瘤体积与血液生物标志物强相关(r=0.7,P<0.01),而CT与68Ga-FAPI最大强度投影定性疗效评估仅弱相关。作者认为68Ga-FAPI PET/CT可能用于疾病疗效评估和随访。
要点
- 6例浸润性小叶乳腺癌患者共行24次68Ga-FAPI PET/CT扫描。
- 68Ga-FAPI肿瘤体积与血液肿瘤生物标志物强相关(r=0.7,P<0.01)。
- CT与68Ga-FAPI最大强度投影定性疗效评估仅弱相关。
核心结论
- 浸润性小叶乳腺癌的进展与消退(经血液生物标志物评估)与68Ga-FAPI肿瘤体积强相关。
- 68Ga-FAPI PET/CT可能用于疾病疗效评估和随访。
研究设计与样本
- 对FAPI高摄取的浸润性小叶乳腺癌患者进行治疗变更前后随访,共6例患者(53±8岁),累计24次扫描(每例基线及2-4次随访扫描)。
- 将68Ga-FAPI最大强度投影定性图像和定量肿瘤体积与CT结果及血液肿瘤生物标志物进行相关性分析。
主要发现
- 68Ga-FAPI肿瘤体积与血液生物标志物强相关(r=0.7,P<0.01)。
- CT与68Ga-FAPI最大强度投影定性疗效评估仅弱相关。
临床怎么用
- 作者认为68Ga-FAPI PET/CT可能用于浸润性小叶乳腺癌的疾病疗效评估和随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68 Ga-fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. METHODS: We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. RESULTS: Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2-4 follow-up scans). We found a strong correlation between 68 Ga-FAPI tumor volume and blood biomarkers ( r = 0.7, P < 0.01), but weak correlation between CT and 68 Ga-FAPI maximal intensity projection-based qualitative response assessment. CONCLUSIONS: We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68 Ga-FAPI tumor volume. 68 Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.
引用
- Eshet Y, Tau N, Levanon K, et al. The Role of 68 Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up. Clin Nucl Med. 2023. PMID: 37339456. doi:10.1097/RLU.0000000000004744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。